Bristol-Myers Squibb Company (BMY) is a Healthcare stock trading at $60.45 (as of 2026-07-17), with a market capitalization of $123.44B and a trailing P/E of 17.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Bristol-Myers Squibb Company develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Its portfolio covers areas such as hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19, and includes therapies including Revlimid, Eliquis, Opdivo, Pomalyst/Imnovid, and Orencia.
Bristol-Myers Squibb (BMY) discovers, develops, licenses, manufactures, and markets biopharmaceutical drugs worldwide, making money primarily from sales of branded therapies such as Eliquis, Revlimid, and Opdivo across multiple therapeutic areas.
BMY's profit power is structurally driven by the size and durability of a concentrated portfolio of marketed branded biopharmaceuticals, especially Eliquis and Revlimid, because the company's reported operating performance is tied to sales across its in-line and new product portfolio.
| Eliquis | $4.1B |
| Revlimid | $1.7B |
| Yervoy | $0.8B |
| Sotyktu | $0.8B |
| Orencia | $0.8B |
| Opdualag | $0.6B |
| Reblozyl | $0.6B |
| Breyanzi | $0.4B |
| Camzyos | $0.4B |
| Zeposia | $0.2B |
| Cobenfy | $0.1B |
| Other (residual) | $1.2B |
Business quality (Solid): The business is built around commercial branded drug sales, and the latest quarter data shows meaningful revenue contribution from large franchises plus a broader in-line and new product portfolio, but performance is naturally sensitive to how those marketed products trend over time.
Valuation: At 16× earnings, BMY trades in line with the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $60.45 |
| Market Cap | $123.44B |
| P/E Ratio | 17.0 |
| EV / EBITDA | 12.0 |
| Price / Book | 6.14 |
| Price / Sales | 2.55 |
| FCF Yield | 9.6% |
| DCF Value (model) | $21.57 |
| DCF Upside vs Price | -64.3% |
| Revenue (TTM) | $48.19B |
| Net Margin | 14.6% |
| Revenue Growth (YoY) | 2.6% |
| EPS Growth (YoY) | 8.3% |
| FCF Growth (YoY) | -55.3% |
| Altman Z-Score | 2.25 (grey) |
| Piotroski F-Score | 8/9 (strong) |
| Stock P/E | 17.0 |
| Sector P/E (Healthcare) | 21.4 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -20.8% |
| vs Industry | 0.0% |
| Top Institutional Holder | VANGUARD GROUP INC ($10.72B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Christopher S. Boerner |
| Employees | 34,100 |
| Country | US |
| IPO Date | 1972-06-01 |
Data as of 2026-07-17.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.